Trevi Therapeutics Inc (TRVI) reports a narrowed net loss and a strong cash position, while navigating regulatory hurdles and ...

Trevi Therapeutics (($TRVI)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Trevi ...

Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026 Company ended ...

Our coverage of the year’s most momentous automotive innovations, as determined by the Automotive Division of the Society of ...

The stock exchange conducted 11,875 Investor Awareness Programs (IAPs) in the first half of FY26 alone, reaching nearly 6.2 ...

The National Stock Exchange of India (NSE) reached another milestone in November 2025, with total unique trading accounts ...

AWS partnership ...

Pre-NDA meeting with FDA to discuss brilaroxazine's path to approval for schizophrenia planned in Q4 2025 - - Potential NDA submission for schizophrenia indication targeted for Q2 2026 - - European ...

Bhubaneswar: The National Stock Exchange of India (NSE) reached another milestone in November 2025, with total unique trading accounts surpassing 24 crore (240 million). This comes just over a ...

Oppenheimer analyst Leland Gershell raised the firm’s price target on Trevi Therapeutics (TRVI) to $24 from $23 and keeps an Outperform rating on ...

London stocks fell sharply on Friday, sterling lost ground and borrowing costs rose amid reports that Chancellor Rachel Reeves has ditched plans to raise income tax at the upcoming Budget, while ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Contineum Therapeutics, Inc. Class A (CTNM – Research Report) and Cytokinetics ( ...